Eris Lifesciences DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	1.12×	1.01×	0.77×	0.92×	0.92×
	0.73×	0.76×	0.70×	0.88×	0.96×
	26.3%	26.9%	24.3%	24.5%	24.9%
	0.43×	0.43×	0.41×	0.37×	0.57×
	1.83×	1.89×	2.15×	2.19×	1.65×
	17.0%	16.8%	11.4%	16.0%	20.9%
	18.3%	18.3%	12.9%	16.4%	18.6%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ERIS₹1,163.60

Eris Lifesciences Ltd.

· Pharma & Health

₹ CrorePeersMANKIND AJANTPHARM TORNTPHARM EMCURE GRANULES CONCORDBIO INDGN CAPLIPOINTMcap ₹16,116 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.92	0.92	0.77	1.01	1.12
Interest Burden (Pretax/EBIT) ×	0.96	0.88	0.70	0.76	0.73
EBIT Margin %	24.90	24.50	24.25	26.86	26.29
Asset Turnover ×	0.57	0.37	0.41	0.43	0.43
Financial Leverage (Assets/Equity) ×	1.65	2.19	2.15	1.89	1.83
ROE (5-step product, year-end total equity) %	20.90	16.00	11.41	16.82	16.98
ROE (owners' profit / average owners' equity) %	18.62	16.39	12.93	18.34	18.34

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.